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Background: Obesity is a common pathology with increasing incidence, and is associated with increased mortality
and healthcare costs. Several treatment options for obesity are currently available ranging from behavioral
modifications to pharmaceutical agents. Many popular dietary supplements claim to enhance weight loss by acting
as metabolic stimulators, however direct tests of their effect on metabolism have not been performed.
Purpose: This work identified the effects popular dietary supplements on metabolic rate and mitochondrial
biosynthesis in human skeletal muscle cells.
Methods: Human rhabdomyosarcoma cells were treated with popular dietary supplements at varied doses for
24 hours. Peroxisome proliferator-activated receptor coactivator 1 alpha (PGC-1α), an important stimulator of
mitochondrial biosynthesis, was quantified using quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR). Mitochondrial content was measured using flow cytometry confirmed with confocal microscopy.
Glycolytic metabolism was quantified by measuring extracellular acidification rate (ECAR) and oxidative metabolism
was quantified by measuring oxygen consumption rate (OCR). Total relative metabolism was quantified using
WST-1 end point assay.
Results: Treatment of human rhabdomyosarcoma cells with dietary supplements OxyElite Pro (OEP) or Cellucore
HD (CHD) induced PGC-1α leading to significantly increased mitochondrial content. Glycolytic and oxidative
capacities were also significantly increased following treatment with OEP or CHD.
Conclusion: This is the first work to identify metabolic adaptations in muscle cells following treatment with popular
dietary supplements including enhanced mitochondrial biosynthesis, and glycolytic, oxidative and total metabolism.
Keywords: Mitochondrial biosynthesis, PGC, Extracellular acidification and oxygen consumption rates, Metabolic
syndrome, Oxidative phosphorylation, Dietary supplementsBackground
Obesity is an increasingly prevalent morbidity with nearly
two thirds of adult Americans overweight, half of whom
are obese [1]. Obesity-related health issues have been
reported to increase healthcare costs by an estimated $147
billion annually [2]. Over the past decade, chemical and* Correspondence: vaughanr@unm.edu
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reproduction in any medium, provided the orbehavioral interventions that favorably modify metabolic
rate have been central to obesity research.
Several over-the-counter dietary supplements claim to
increase metabolic rate and enhance fatty acid catabol-
ism. Of the available over-the-counter (OTC) dietary
supplements, OxyElite Pro (OEP) produced by USP La-
boratory and Cellucore Super HD (CHD) are purported
to increase metabolic rate and fat metabolism [3].
OEP has been shown to increase markers of fat
mobilization, metabolic rate (measured via indirect calor-
imetry), and reduce bodyweight and body fat (estimated
via Dual-energy X-ray absorptiometry) in healthy youngal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dimethylamylamine (also known as germanium, gerana-
mine or DMAA) has been implicated for potential contra-
indications. DMAA is purported to increase both systolic
and diastolic blood pressure in young and healthy men
and women immediately following ingestion, although
these observations have been inconsistent during longer
treatments with OEP in young men [4-7]. DMAA is also
purported to cause false-positive results for amphetamines
on select immunoassays, a profound implication for ath-
letes with sanctioned governing bodies [8]. CHD, a newer
dietary supplement has very limited research regarding
safety or efficacy. CHD is advertised to increase metabolic
rate and decrease fatty acid synthesis. Many of the ingredi-
ents including caffeine have been previously linked to
increased metabolic rate. Moreover, because supplements
commonly contain a variety of ingredients in proprietary
blend forms, and few controlled studies have been per-
formed to address the metabolic effects at the cellular
level, further work is needed to identify possible metabolic
effects. This work specifically addresses the effects that
treatment with OEP or CHD supplements have on metab-
olism in human skeletal muscle cells.
Peroxisome proliferator-activated receptor coactivator
1 alpha (PGC-1α) is a transcriptional coactivator that is
essential for mitochondrial biosynthesis and activates
genes that regulate energy homeostasis and metabolism
[9-11]. PGC-1α increases fatty acid oxidation through
increased peroxisome proliferator-activated receptor
alpha (PPARα) expression, which increases forkhead box
protein 1 (FOXO1), nuclear respiratory factors 1 and 2
(NRF1/2) and other factors influencing fat oxidation
[12-14]. PGC-1α is also an important signaling molecule
in the activation and regulation of gluconeogenesis,
which is likely mediated through FOXO1 and estrogen-
related receptor alpha (ERR-α) [12,15-18]. Thus, PGC-
1α modifies metabolic rate and expression of genes
involved in gluconeogenesis, fat oxidation and mito-
chondrial biosynthesis [12-18].
Clinically, the relationship between low PGC-1α ex-
pression and type II diabetes/obesity has been identified
[19-22]. Low PGC-1α is also associated with reduced ex-
pression of oxidative phosphorylation genes, decreasing
fatty acid oxidation and energy utilization [19,23,24].
Treatment with the PGC-1α stimulator Rosiglitazone
(through binding and activating PPARγ) increased mito-
chondrial density and function, while improving insulin
sensitivity [25]. Further evidence suggests that an in-
crease in PGC-1α (independent of Rosiglitazone) can
improve insulin sensitivity and improve muscle function
[25]. It has also been identified that PGC-1α is essential
for the recovery from the diminished ATP caused by
chemical uncoupling as evidenced by the lack of recov-
ery in PGC-1α null cells and animals [26].Treatment with potent research-grade chemicals such
as 2,4-dinitrophenol (DNP) and p-trifluromethoxy phe-
nylhydrazone (FCCP) have been shown to induce PGC-
1α in fibroblasts [26]. Moreover, our laboratory recently
identified that treatment with DNP or caffeine can in-
duce PGC-1α, and increase both metabolic rate and
mitochondrial content in muscle cells suggesting that
commercially available metabolic stimulators might have
similar effects [27]. The well documented effects of
PGC-1α on metabolism suggest that modulation of
PGC-1α expression is a potential strategy for altering
metabolic rate.
Purpose- This work seeks to explore effects of treat-
ment with OTC dietary supplements on mitochondrial
and glycolytic metabolism in skeletal muscle cells.
Human rhabdomyosarcoma cells are a naturally immor-
talized cell model, frequently used for making inferences
about muscle tissue adaptations [27-31]. We show that
treatment of muscle cells with OEP or CHD at varied
doses induce PGC-1α mRNA and protein in a dose and
time sensitive manner. We also illustrate that treatment
with either OEP or CHD increase mitochondrial con-
tent. This work identifies for the first time the effects
that several OTC diet supplements have on mitochon-
dria content and cell metabolism in muscle cells.
Methods
Cell culture
Homo sapiens rhabdomyosarcoma cells were purchased
from ATCC (Manassas, VA). Cells were cultured in Dul-
becco’s Modified Eagle’s Medium (DMEM) containing
4500mg/L glucose and supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 100U/mL peni-
cillin/streptomycin, in a humidified 5% CO2 atmosphere
at 37°C. Trypsin-EDTA at 0.25% was used to detach the
cells for splitting and re-culturing. Stock Oxy Elite
ProTM (OEP) from USP Labs (Dallas, TX) and stock Cel-
lucore HDTM (CHD) from Cellucore (Bryan, TX) pur-
chased over the counter were diluted to 2 dilutions that
contain equivalent ingredient by weight; high dose con-
taining 90 μg/ml or low dose containing 45 μg/ml. Dose
and exposure times were determined through pilot
experiments to significantly increase PGC-1α (data not
shown). Final concentration of ethanol was 0.1% for all
treatments.
Quantitative real-time polymerase chain reactions
(qRT-PCR)
Cells were seeded in 6-well plates at a density of 1 x 106
cells/well, treated and incubated as described above for 12
or 24 hours. Following incubation, total RNA was
extracted using RNeasy Kit from Qiagen (Valencia, CA)
and total RNA was quantified by Nanodrop spectropho-
tometry. RNA (5000 ng/sample) was denatured at 75°C
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decamers and Moloney murine leukemia virus reverse
transcriptase (MMLVRT) from the Retroscript™ RT kit
from Ambion (Austin, TX) for 60 minutes at 42°C and the
enzyme denatured at 92°C for 10 minutes. PCR primers
were designed using Primer Express software from Invi-
trogen (Carlsbad, CA) and synthesized by Integrated DNA
Technologies (IDT; Coralville, IA). For PGC-1α, the for-
ward primer was 5’-ACCAAACCCACAGAGAACAG-3’
and the reverse primer was 5’-GGGTCAGAGGAAG
AGATAAAGTTG-3’. Amplification of PGC-1α was
normalized to the housekeeping gene, TATA Bin-
ding Protein (TBP). For TBP, the forward primer was
5’-CACGAACCACGGCACTGATT-3’ and the reverse
primer was 5’-TTTTCTTGCTGCCAGTCTGGAC-3’.
qRT-PCR reactions were performed in triplicate using
the LightCycler 480 real-time PCR system from Roche
Applied Science, (Indianapolis, IN). SYBR Green based
PCR was performed in triplicate using an estimated 800
ng of cDNA per well to ensure a strong signal; final pri-
mer concentrations were 10 μM in a total volume of
30μl. The following cycling parameters were used: 95°C
for 10 minutes followed by 45 cycles of 95°C for 15 sec-
onds, and 60°C for one minute. Relative expression levels
were determined by the change in crossing points of re-
action amplification (ΔΔCp method) between PGC-1α
and TBP for each treatment compared with the control
group [32].
Flow cytometry
Cells were plated in 6-well plates at a density of 1.2 x 106
cells/well treated in triplicate and incubated as previ-
ously described above for 24 hours. Following treat-
ment, the media was removed and the cells were re-
suspended in pre-warmed media with 200 nM
Mitotracker Green from Life Technologies (Carlsbad,
CA) and incubated for 45 minutes in a humidified 5%
CO2 atmosphere at 37°C. The cells were pelleted, the
media with Mitotracker was removed and the cells were
suspended in pre-warmed media. Group mean fluores-
cence was measured using Facscalibur filtering 488nm.
Microscopy and immunohistochemistry
Chamber-slides from BD Bioscience (Sparks, MD), were
seeded with 5000 cells/well. To verify PGC-1α protein
expression, cells were cultured and treated for 24 hours
as described above. Cells were fixed using 3.7% formal-
dehyde in media, permiabilized with PBS with 0.1% Tri-
ton 100X from Sigma (St. Louis, MO) for 10 minutes
and blocked for 1 hour with PBS with 0.1% Triton 100X
and 3.0% BSA from Sigma (St. Louis, MO). Cells were
stained with an anti-PGC-1α primary polyclonal anti-
body from Santa Cruz Biotechnologies (Santa Cruz, CA)
at 1:200 dilution in PBS with 0.1% BSA overnight. Thecells were rinsed with PBS with 0.1% Triton 100X and
3.0% BSA, and secondary anti-rabbit AlexFluor 633 anti-
body from Invitrogen (Carlsbad, CA) was applied in
1:200 dilution. Slides were mounted with Prolong Gold
with DAPI from Invitrogen (Carlsbad, CA) and cured
overnight. Cells were imaged using the Axiovert 25
microscope with AxioCam MRc from Zeiss (Thorn-
wood, NY). To verify increased mitochondrial content,
the cells were then stained with Mitotracker 200 nM
from Invitrogen (Carlsbad, CA) for 45 minutes, and
fixed in 3.7% formaldehyde in pre-warmed media. Cells
were mounted, cured and imaged as described above.
Metabolic assay
Cells were seeded overnight in 24-well culture plate from
SeaHorse Bioscience (Billerica, MA) at density 5 x 105
cells/well, treated and incubated for 24 hours as
described above. Following treatment, culture media was
removed and replaced with XF Assay Media from Sea-
Horse Bioscience (Billerica, MA) containing 4500mg/L
glucose free of CO2 and incubated at 37°C. Per manufac-
tures’ protocol, SeaHorse injection ports were loaded
with oligomycin, an inhibitor of ATP synthase which
induces maximal glycolytic metabolism and reveals en-
dogenous proton leak (mitochondrial uncoupling) at a
final concentration 1.0 μM. Oligomycin addition was fol-
lowed by the addition of carbonyl cyanide p-[trifluoro-
methoxy]-phenyl-hydrazone (FCCP), an uncoupler of
electron transport that induces peak oxygen consump-
tion (an indirect indicator of peak oxidative metabolism)
at final concentration 1.25 μM. Rotenone was then
added in 1.0 μM final concentration to reveal non-
mitochondrial respiration and end the metabolic reac-
tions [33,34]. Extracellular acidification, an indirect
measure of glycolytic capacity, and oxygen consumption,
a measure of oxidative metabolism was measured using
the SeaHorse XF24 Extracellular Analyzer from Sea-
Horse Bioscience (Billerica, MA). SeaHorse XF24 Extra-
cellular Analyzer was run using 8 minute cyclic protocol
commands (mix for 3 minutes, let stand 2 minutes, and
measure for 3 minutes) in triplicate.
WST1 Metabolic assay
WST-1 is a widely used reagent that is metabolized by
mitochondrial dehydrogenases through consumption of
reduction potential resulting in the fluorescence indicat-
ing changes in metabolism, cell proliferation and viabil-
ity. We used the WST-1 assay as an indirect measure of
cellular reduction potential which indicates cellular en-
ergy status. Cells were seeded in 96-well plates at density
5,000 cells/well and grown over night. Cells were then
treated with either ethanol control, or one of the desig-
nated OTC supplement treatments and incubated as
previously described above for 24 hours. Media and
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containing 10% WST1 reagent was added to each well
and incubated as previously described above. Fluores-
cence was measured 1 hour following WST1 addition
using Wallac Victor3V 1420 Multilabel Counter from
PerkinElmer (Waltham, MA).
Cell viability
Cells were seeded for 24 hours in 6-well plate with density
1.2 x 106 cells/well and treated in triplicate and incubated
as previously described above for 24 hours. Trypan blueFigure 1 Group mean PGC-1α RNA and protein expression ±SD. A- Re
rhabdomyosarcoma cells with OEP or CHD at 90 μg/ml (High) or 45 μg/ml
B- Relative induction of PGC-1α RNA following similar treatment for 24 hou
from confocal microscopy in (D) using 7 cells per treatment (n = 7) followi
compared with ethanol control. D- Confocal microscopy of PGC-1α protein
Dapi nuclear stain (blue), PGC-1α protein (red), and green line represents 5
p < 0.001.from Sigma (St Louis, MO) exclusion staining was used to
assess cell number and viability using Countess from Invi-
trogen (Carlsbad, CA) cell quantification system.
Statistical analysis
PGC-1α expression, flow cytometry, metabolic assays
and cell viability were analyzed using ANOVA with
Dunnett’s post hoc test and pairwise comparisons were
used to compare treatments with control. WST1 cell
metabolism analysis was performed using ANOVA and
pairwise comparisons comparing treatments withlative induction of PGC-1α RNA following treatment of
(Low) for 12 hours compared with ethanol control (control =1).
rs. C- Immunofluorescent quantification of PGC-1α protein expression
ng treatment with OEP or CHD at 90 μg/ml (High) for 24 hours
expression of cells treated as described above for 24 hours. NOTES:
0 μm. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates
Figure 2 Group mean mitochondrial content ±SD. A- Flow cytometric group mean log fluorescence of rhabdomyosarcoma cells measured in
triplicate using 10,000 cells per sample, treated with OEP or CHD at 90 μg/ml (High) or 45 μg/ml (Low). B- Immunofluorescent quantification of
cells treated as described above for 24 hours using 7 cells per treatment (n = 7). C- Confocal microscopy images of cells treated as described
above for 24 hours. NOTES: Dapi nuclear stain (blue), mitochondrial stain (green), and red line represents 50 μm. * indicates p < 0.05, ** indicates
p < 0.01 and *** indicates p < 0.001.
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fluorescence and data normalization to control (control
metabolic rate = 1). Values of p < 0.05 indicated statis-
tical significance in all tests and Prism from GraphPad
(La Jolla, CA) was used to perform all statistical
analyses.
Results and discussion
PGC-1α expression and mitochondrial content
PGC-1α RNA was significantly induced following treatment
for 12 or 24 hours with OEPHigh and Low or CHDLow
compared with the control group (Figure 1A and B, respect-
ively). PGC-1α protein was imaged using confocal micros-
copy and quantified with ImageJ using 7 cells per treatment
(n = 7) which revealed significantly elevated PGC-1α protein
following treatment for 24 hours with OEPHigh or
CHDHigh (Figure 1C and D). Flow cytometry with
Mitotracker staining showed that treatment for 24 hours
with either OEP or CHD significantly increased mitochon-
drial content compared with ethanol control (Figure 2A).
We used confocal microscopy to verify flow cytometry
observations that OEP or CHD treated cells had increased
mitochondrial content (Figure 1B and C).Figure 3 Group mean glycolytic metabolism ±SD. A- Extracellular acidif
ethanol control (final concentration = 0.1%) or OEP or CHD at 90 μg/ml (H
above. C- Peak ECAR following addition of oligomycin, an inhibitor of oxid
rate (OCR) following addition of carbonyl cyanide p-[trifluoromethoxy]-phe
previously added oligomycin. NOTES: * indicates p < 0.05, ** indicates p <Glycolytic metabolism
In order to quantify changes in glycolytic metabolism,
we measured extracellular acidification rate (ECAR),
which was significantly increased in cells treated with
high dose supplements (Figure 3A). Treatment with ei-
ther OEPHigh or CHDHigh significantly increased basal
glycolysis compared with control (Figure 3B). Treatment
with either OEPHigh or CHDHigh also significantly
increased peak glycolytic capacity compared with control
(Figure 3C). OEPHigh or CHDHigh treatment also sig-
nificantly elevated glycolytic use during induction of
peak oxidative metabolism compared with the control
group (Figure 3D). Cells treated with low-dose OEP or
CHD did not have greater basal or peak glycolytic cap-
acity compared with control (data not shown).
Oxidative metabolism
In order to quantify changes in oxidative metabolism,
we measured oxygen consumption rate (OCR) which
was also elevated in cells treated with high dose OEP or
CHD (Figure 4A). Treatment with either OEPHigh or
CHDHigh significantly increased basal oxidative metab-
olism compared with control (Figure 4B). Treatmentication rate (ECAR) of rhabdomyosarcoma cells treated with either
igh) for 24 hours. B- Baseline ECAR following treatment described
ative phosphorylation. D- Peak ECAR during peak oxygen consumption
nyl-hydrazone (FCCP), a mitochondrial uncoupling agent, in addition to
0.01, and *** indicates p < 0.001 compared with control.
Figure 4 Group mean oxidative metabolism ±SD. A- Oxygen consumption rate (OCR) of rhabdomyosarcoma cells treated with either ethanol
control (final concentration = 0.1%) or OEP or CHD at 90 μg/ml (High). B- Baseline OCR following treatment described above. C- OCR during peak
ECAR following addition of oligomycin, an inhibitor of oxidative phosphorylation. D- Peak OCR following addition of carbonyl cyanide
p-[trifluoromethoxy]-phenyl-hydrazone (FCCP), a mitochondrial uncoupling agent, in addition to previously added oligomycin. NOTES: * indicates
p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
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increased oxidative metabolism during peak glycolytic
capacity compared with control, an indicator of
increased endogenous mitochondrial uncoupling (or po-
tentially chemically-induced uncoupling) (Figure 4C).
Unexpectedly, only treatment with CHDHigh signifi-
cantly elevated peak oxidative metabolism compared
with the control group (Figure 4D). Cells treated with
low-dose OEP or CHD did not consistently exhibit
greater basal or peak oxidative metabolism capacity
compared with control (data not shown). Only OEPHigh
exhibited significantly greater oxygen consumption com-
pared with the control following addition of rotenone,
an indirect measure of non-mitochondrial respiration
(data not shown).
Cellular oxidative reliance
To quantify changes in cellular reliance on oxidative me-
tabolism, we compared ECAR versus OCR. Oxidative re-
liance, indicated by a ratio of OCR:ECAR was
significantly increased in cells treated with high dose
OEP or CHD (Figure 5A). Specifically, cells treated
with OEPHigh or CHDHigh demonstrated significantlygreater reliance on oxidative metabolism during basal
measurements and during peak glycolysis compared
with the control group (Figure 5C and D, respectively).
Basal metabolic rate
To quantify changes in metabolic rate, we compared
ECAR versus OCR. Cells treated with OEPHigh or
CHDHigh exhibited a significantly greater basal ECAR
and OCR, indicating increased metabolic rate (Figure 6A).
Moreover, cellular metabolism indicated by WST-1 assay
was significantly increased in cells treated with either
dietary supplement compared with control. Both OEP
and CHD increased metabolism in a dose-dependent
manner compared with ethanol control (Figure 6B). To
assess the effect of supplement treatment on cell viabil-
ity, we used Trypan blue exclusion measured by Count-
ess Cell Counter. Following 24 hour of treatment with
either ethanol or either of the supplements at either
dose, cell viability was not statistically different from
control (data not shown).
This work identified several effects that dietary supple-
ments OEP and CHD have on metabolism and cellular
adaptation in skeletal muscle cells. First, we illustrated
Figure 6 A- Group mean basal metabolic rate ± SD of rhabdomyosarcoma cells treated with either ethanol control (final concentration
= 0.1%) or OEP or CHD at 90 μg/ml (High) plotted as ECAR versus OCR (data from SeaHorse assay). B- Change in metabolic rate derived
from reciprocal log fluorescence from WST1 metabolic assay with control = 1 indicating change in reduction potential within each well treated
with either 0.1% ethanol or OEP or CHD at 90 μg/ml (High) or 45 μg/ml (Low). NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates
p < 0.001 compared with control.
Figure 5 Group mean oxidative reliance ±SD. A- Metabolic reliance expressed as the ratio of oxygen consumption rate (OCR) extracellular
acidification rate (ECAR) OCR:ECAR illustrating metabolic rate. B Oxidative reliance represented by a ratio of OCR:ECAR at baseline. C- Oxidative
reliance during peak glycolysis. D- Oxidative reliance during peak oxidation. NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates
p < 0.001 compared with control.
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density and content in part through induction of meta-
bolic transcription factor PGC-1α. Flow cytometry and
microscopy experiments verified that cells treated with
either supplement exhibited significantly greater mito-
chondrial content versus ethanol control. We also
employed metabolic experiments which identified that
both oxidative and total metabolism were significantly
increased by both supplements compared with control.
WST-1 assay observations in combination with insignifi-
cant changes in cell viability also support the observa-
tion that both treatments significantly increased cellular
metabolism.
Collectively, these results support the notion that sti-
mulators of PGC-1α and mitochondrial metabolism may
have implications for many different metabolic diseases
such as diabetes and obesity [19-21,25]. Previously, our
lab has demonstrated that polyunsaturated fatty acids
are dietary constituents which stimulate PGC-1α and
mitochondrial metabolism in skeletal muscle cells [35].
Our current observations demonstrate the stimulatory
effect of dietary supplements and support several of the
previous examinations of the effects of OEP on whole
body metabolism [3,4]. This report is among the first to
demonstrate that the relatively new dietary supplement
CHD also increases metabolism. Lastly, this report is
among the first to show an increase in mitochondrial
content following treatment with OEP and CHD.
Limitations
Our experiments were performed using a cancerous
myoblast model known to favor glycolytic metabolism as
opposed to oxidative metabolism, which may make our
observations less generalizable to healthy mature skeletal
muscle. Additionally, we prepared culture media per
ATCC recommendations containing high glucose; an en-
vironment previously shown to induce insulin resistance
in L6-myotubes [36]. It would be interesting to examine
the effects these supplements elicit from mature, differ-
entiated myotubes in various media. Further research is
needed to elucidate the depth of cellular effects that
these potent metabolic stimulators may have on meta-
bolic diseases such as diabetes.
Conclusion
Manipulation of mitochondrial function provides many
appealing possibilities for the treatment of several dis-
eases including obesity. This work illustrates that, al-
though much of the biochemical framework has been
completed, there is still much to learn about the role
that PGC-1α can play in the treatment of various disease
states. Further research is needed to identify both behav-
ior modifications and chemical agents that can elicit an
increase in mitochondria, because of the role thatdiminished mitochondria play in chronic diseases. It
appears that increased PGC-1α expression and activa-
tion accompanied by increased mitochondrial biosyn-
thesis, may be a viable treatment option for diseases
such as obesity.
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